Literature DB >> 27173419

Fatal pulmonary arterial hypertension in an infant girl with incontinentia pigmenti.

Kenji Yasuda1, Noriaki Minami1, Yoko Yoshikawa1, Takeshi Taketani1,2, Seiji Fukuda1, Seiji Yamaguchi1.   

Abstract

We report the case of an infant girl with incontinentia pigmenti (IP) complicated by fatal pulmonary arterial hypertension (PAH). She was diagnosed with IP, based on the presence of specific skin lesions, neonatal seizures, hypereosinophilia and a maternal family history of IP. At the age of 2 months, she was diagnosed with PAH on systolic heart murmur due to tricuspid valve regurgitation. Despite several treatments for PAH but not including epoprostenol, severe PAH persisted and she died of pulmonary hypertensive crisis at the age of 5 months. On postmortem histopathology the pulmonary artery had severe intimal thickening, with occlusion or stenosis of the vascular lumen of the small pulmonary arteries as well as partial plexiform lesions, all of which were compatible with PAH. Modulation of nuclear factor-κB signaling may be involved in the development of PAH in IP.
© 2016 Japan Pediatric Society.

Entities:  

Keywords:  incontinentia pigmenti; intimal thickening; nuclear factor-κB essential modulator gene; plexiform lesion; pulmonary arterial hypertension

Year:  2016        PMID: 27173419     DOI: 10.1111/ped.12831

Source DB:  PubMed          Journal:  Pediatr Int        ISSN: 1328-8067            Impact factor:   1.524


  2 in total

1.  Pulmonary hypertension and vasculopathy in incontinentia pigmenti: a case report.

Authors:  Abduljabbar Alshenqiti; Marwan Nashabat; Hissah AlGhoraibi; Omar Tamimi; Majid Alfadhel
Journal:  Ther Clin Risk Manag       Date:  2017-05-09       Impact factor: 2.423

2.  A case of reversible pulmonary arterial hypertension associated with incontinentia pigmenti.

Authors:  Veronique Atallah; Mathilde Meot; Manoelle Kossorotoff; Louise Galmiche-Rolland; Claude Lardeux; Benedicte Neven; Christine Bodemer; Damien Bonnet
Journal:  Pulm Circ       Date:  2018-07-23       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.